OR WAIT null SECS
GlaxoSmithKline has issued a voluntary recall of three lots of respiratory inhalers in the United Kingdom, including preventer and emergency relief inhalers.
On Feb. 21, 2018, the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom’s regulatory authority, issued a recall of three specific affected lots of respiratory inhalers manufactured by GlaxoSmithKline (GSK).
The recalled lots contained Seretide Accuhaler (50/250 mcg) and Ventolin Accuhaler (200 mcg). Two affected batches of Ventolin Accuhaler and one affected batch of Seretide were distributed to the UK market. MHRA reports that only a small proportion of the units are defective.
One lot of Seretide Accuhaler, which MHRA reports is used for the maintenance of preventative treatment of asthma, is being recalled from hospitals, pharmacies, dispensing practices, retailers, and wholesalers in the UK. The recall of Seretide Accuhaler is at pharmacy-level because it is used for maintenance treatment as opposed to a reliever treatment, according to MHRA.